Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.

Canadian journal of gastroenterology & hepatology - 1 Sept 2014

Yau Alan Hoi Lun, Yoshida Eric M

Abstract excerpt

Between 2001 and 2011, the standard of care for chronic hepatitis C virus (HCV) infection was a combination of pegylated interferon (PEG-IFN) and ribavirin (RBV). In May 2011, boceprevir and telaprevir, two first-generation NS3/4A protease inhibitors, were approved in combination with PEG-IFN and RBV for 24 to 48 weeks in hepatitis C virus genotype 1 infections. In December 2013, simeprevir, a second-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Approval

Share to Drug Resistance, Viral

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferons

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 25229466
DOI: 10.1155/2014/549624
PMCID: PMC4210236

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.PMID 25229466Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

New hepatitis C therapies: the toolbox, strategies, and challenges.Semantic proximity Read ↗

Direct-acting antivirals: the endgame for hepatitis C?Semantic proximity Read ↗

Future perspectives: towards interferon-free regimens for HCV.Semantic proximity Read ↗

Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.Semantic proximity Read ↗

Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection.Semantic proximity Read ↗

Ideal oral combinations to eradicate HCV: The role of ribavirin.Semantic proximity Read ↗

Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?Semantic proximity Read ↗

Interferon-free regimens: the near future, the likely and the not so likely.Semantic proximity Read ↗

Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.Semantic proximity Read ↗

Interferon-free regimens for hepatitis C: combine and conquer.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.